ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Randomized ZUMA‑7 Study of Axi-Cel vs. Standard‑of-Care Therapy in R/R LBCL"

0 views
June 7, 2023
Comments 0
Login to view comments. Click here to Login